Attention-deficit hyperactivity disorder: Recent advances in paediatric pharmacotherapy

Drugs

Volumn 70, Issue 1, 2010, Pages 15-40

  May, Diane E ^a   Kratochvil, Christopher J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CLONIDINE; DEXMETHYLPHENIDATE; FLUOXETINE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PAROXETINE; PRODRUG; QUINIDINE;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; ANOREXIA; ANXIETY DISORDER; APATHY; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLOOD PRESSURE; BLURRED VISION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CHILD; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG ABUSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HOSTILITY; HUMAN; HYPOTENSION; INSOMNIA; IRRITABILITY; ISOMER; LABORATORY TEST; LETHARGY; LIVER INJURY; MANIA; MONOTHERAPY; MOOD CHANGE; MORNING DOSAGE; NERVOUSNESS; ORTHOSTATIC BLOOD PRESSURE; PSYCHOSIS; PULSE PRESSURE; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE THRESHOLD; SIDE EFFECT; SKIN ABSORPTION; SKIN ALLERGY; SKIN IRRITATION; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; SUDDEN DEATH; SUICIDE; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TIC; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLONIDINE; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HALF-LIFE; HEALTH CARE COSTS; HUMANS; METHYLPHENIDATE; PEDIATRICS; PRODRUGS; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 73349141708     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11530540-000000000-00000     Document Type: Review

References (160)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Text rev, 4th ed. Washington, DC: American Psychiatric Association, 2000
2. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001 Oct; 108 (4): 1033-1044
3. American Academy of Pediatrics Committee on Quality Improvement and Subcommittee on Attention-Deficit/ Hyperactivity Disorder. Treatment of attention deficit/ hyperactivity disorder: overview of the evidence. Pediatrics 2005 Jun; 115 (6): E749-57
4. Greenhill LL, Pliszka S, Dulcan MK, et al. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002 Feb; 41 (2 Suppl.): 26-49S
5. Pliszka S. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007 Jul; 46 (7): 894-921
6. Eli Lilly and Company. Strattera® (atomoxetine hydrochloride) capsules for oral use: prescribing information [online]. Available from URL: http://pi.lilly.com/us/ strattera-pi.pdf [Accessed 2009 Oct 4]
7. Novartis Pharmaceuticals Corporation. Focalin-XR (dexmethylphenidate hydrochloride) extended-release capsules for oral use: prescribing information [online]. Available from URL: http://www.pharma.us.novartis. com/product/pi/pdf/focalinXR.pdf [Accessed 2009 Jul 18]
8. Shire US, Inc. Vyvanse® (lisdexamfetamine dimesylate) capsules: prescribing information [online]. Available from URL: http://www.vyvanse.com/ pdf/prescribing-information. pdf [Accessed 2009 Jun 18]
9. Novartis Pharmaceuticals Corporation. Ritalin SR® (methylphenidate HCl) sustained-release tablets: full prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/rital in-ritalin-sr.pdf [Accessed 2009 Oct 4]
10. Novartis Pharmaceuticals Corporation. Ritalin LA® (methylphenidate HCl) extended-release capsules: full prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ritalin- ritalin-sr.pdf [Accessed 2009 Oct 4]
11. UCB Manufacturing, Inc. Metadate CD® (methylphenidate HCl) extended-release capsules: full prescribing information [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda-docs/label/2009/ 021259s021lbl.pdf [Accessed 2009 Oct 4]
12. Ortho-McNeil-Janssen Pharmaceuticals Inc. Concerta® (methylphenidate HCl) extended-release tablets: full prescribing information [online]. Available from URL: http://www.concerta360.com/mcneilpediatrics360/assets/ concerta360/Prescribing-Info.pdf [Accessed 2009 Jul 18]
13. Shire US Inc. Adderall XR® capsules: full prescribing information [online]. Available from URL: http://www. adderallxr.com/pdf/AXR-FPI.pdf [Accessed 2009 Oct 4]
14. Catalent Pharma Solutions. Dexadrine® Spanule® sustained-release capsules: full prescribing information [online]. Available from URL: http://www.gskus.com/products/ assets/us-dexedrine.pdf [Accessed 2009 Oct 4]
15. Boehringer Ingelheim Pharmaceuticals Inc. Catapres (clonidine hydrochloride, USP): prescribing information [online]. Available from URL: http://bidocs.boehringer-ingelheim. com/BIWebAccess/ViewServlet.ser?docBase= renetnt& folderPath=/Prescribing+Information/PIs/Catapres+Tabs/ CatapresTabs.pdf [Accessed 2009 Oct 4]-stream.asp?product-group=1244&p= pi&language=E-stream.asp?product-group=1244&p=pi&language=E [Accessed 2009 Nov 14]
16. Watson Laboratories, Inc. Guanfacine hydrochloride: U.S. prescribing information [online]. Available from URL: http://pi.watson.com/data
17. Biederman J, Spencer TJ. Psychopharmacological interventions. Child Adolesc Psychiatr Clin N Am 2008 Apr; 17 (2): 439-458
18. Brams M, Mao AR, Doyle RL. Onset of efficacy of longacting psychostimulants in pediatric attention-deficit/ hyperactivity disorder. Postgrad Med 2008 Sep; 120 (3): 69-88
19. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin Ther 2008 May; 30 (5): 942-957
20. Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analy-sis. Med Gen Med 2006 Oct; 8 (4): 4
21. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990 Aug; 86 (2): 226-237
22. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morning-only and morning/late afternoon adderall to morning-only, twice-daily, and three times-daily methyl-phenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 1999 Dec; 104 (6): 1300-1311
23. Smith BH, Pelham WE, Gnagy E, et al. Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. J Am Acad Child Adolesc Psychiatry 1998 Mar; 37 (3): 314-321
24. Swanson JM, Wigal SB, Wigal T, et al., COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention deficit/hyperactivity disorder in the laboratory school (The Comacs Study). Pediatrics 2004 Mar; 113 (3): E206-16
25. Barbaresi WJ, Katusic SK, Colligan RC, et al. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr 2007 Aug; 28 (4): 274-287
26. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed byresearch criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990 Oct; 29 (5): 546-557 (Pubitemid 20235340)
27. Biederman J, Monuteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009 Jul; 124 (1): 71-78
28. Charles L, Schain R. A four-year follow-up study of the effects of methylphenidate on the behavior and academic achievement of hyperactive children. J Abnorm Child Psychol 1981 Dec; 9 (4): 495-505
29. Hanc T, Cieslik J. Growth in stimulant-naive children with attention-deficit/hyperactivity disorder using cross-sectional and longitudinal approaches. Pediatrics 2008 Apr; 121 (4): E967-74
30. Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 2009 Jul; 155 (1): 84-89
31. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of youths treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009 May; 48 (5): 484-500
32. Powers RL, Marks DJ, Miller CJ, et al. Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome. J Child Adolesc Psychopharmacol 2008 Oct; 18 (5): 449-459
33. Hinshaw SP, Owens EB, Sami N, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into adolescence: evidence for continuing cross-domain impairment. J Consult Clin Psychol 2006 Jun; 74 (3): 489-499
34. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008 May; 165 (5): 597-603
35. Brinker A, Mosholder A, Schech SD, et al. Indication and use of drug products used to treat attention-deficit/ hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood. J Child Adolesc Psychopharmacol 2007 Jun; 17 (3): 328-333
36. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 2005 Jun 1; 57(11): 1442-1451
37. Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry 2009 Jan; 65 (1): 46-54
38. Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008 May; 165 (5): 604-609
39. Tuerck D, Wang Y, Maboudian M, et al. Similar bio-availability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate, immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther 2007 Dec; 45 (12): 662-668
40. Quinn D, Wigal S, Swanson J, et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004 Nov; 43 (11): 1422-1429
41. Novartis Pharmaceuticals Corporation. Focalin® dex-methylphenidate hydrochloride tablets: prescribing information [online]. Available from URL: http://www.pharma. us.novartis.com/product/pi/pdf/focalin.pdf [Accessed 2009 Oct 4]
42. Davids E, Zhang K, Tarazi FI, et al. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology 2002 Feb; 160 (1): 92-98 (Pubitemid 34169830)
43. Teo SK, Stirling DI, Thomas SD, et al. Neuro-behavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats. Pharmacol Biochem Behav 2003 Feb; 74 (3): 747-754
44. Fischer R, Schutz H, Grossmann M, et al. Bioequivalence of a methylphenidate hydrochloride extended-release preparation: comparison of an intact capsule and an opened capsule sprinkled on applesauce. Int J Clin Pharmacol Ther 2006 Mar; 44 (3): 135-141
45. Lee L, Kepple J, Wang Y, et al. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm Drug Dispos 2003 Sep; 24 (6): 233-243
46. Teo SK, Scheffler MR, Wu A, et al. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. J Clin Pharm 2004 Feb; 44 (2): 173-178
47. Greenhill L, Muniz R, Ball RR, et al. Efficacy and safety of extended release dexmethylphenidate capsules in children with attention-deficit/hyper activity disorder. J Am Acad Child Adolesc Psychiatry 2006 Jul; 45 (7): 817-823
48. Conners CK. A teacher rating scale for use in drug studies with children. Am J Psychiatry 1969 Dec; 126 (6): 884-888
49. Silva RR, Muniz R, Pestreich L, et al. Efficacy and duration of effect of extended release, dexmethylphenidate versus placebo in school children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2006 Jun; 16 (3): 239-251
50. Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 199-208
51. Murray DW, Bussing R, Fernandez M, et al. Psychometric properties of teacher SKAMP ratings from a community sample. Assessment 2009 Jun; 16 (2): 193-208
52. Wigal S, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998; 34 (1): 47-53
53. Brams M, Muniz R, Childress A, et al. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 2008 Oct; 22 (8): 693-704
54. Silva R, Muniz R, McCague K, et al. Treatment of children with attention-deficit/hyper activity disorder: results of a randomized, multicenter, double-blind, crossover study of extended release dexmethylphenidate, d,l-methylpheni-date and placebo in a laboratory classroom setting. Psychopharmacol Bull 2008; 41 (1): 19-33
55. Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyper activity disorder: a 12-hour laboratory classroom study. J Child and Adol Psychopharmacol 2008 Jun; 18 (3): 248-256
56. Shire Pharmaceuticals Ireland Limited. Daytrana™ (methylphenidate transdermal system): prescribing information [online]. Available from URL: http://www.daytrana. com/downloads/DaytranaPrescribingInfo.pdf [Accessed 2009 Sep 21]
57. Pierce D, Dixon CM, Wigal SB, et al. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J Child Adolesc Psychopharmacol 2008 Aug; 18 (4): 355-364
58. Gonzalez MA, Campbell D, Rubin J. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19 (3): 227-232
59. Weiss M, Hechtman L, Turgay A, et al. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007 Oct; 17 (5): 675-688
60. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008 Jan; 69 (1): 149-159
61. Wilens TE, Boellner SW, Lopez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyper activity disorder. J Am Acad Child Adolesc Psychiatry 2008 Jun; 47 (6): 700-708
62. Arnold LE, Lindsay RL, Lopez RA, et al. Treating attention-deficit/ hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007 Nov; 120 (5): 1100-1158
63. Pelham WE, Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jun; 44 (6): 522-529
64. Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methyphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 2005 May; 13 (2): 111-126
65. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006 Feb; 9 (3): 476-485
66. Farone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 2007 Sep; 46 (9): 1138-1147
67. Guy W. ECDEU Assessment manual for psychopharmacology. 2nd ed. Washington, DC: US Government Printing Office, 1976. DHEW Publication no. ABM 76-388
68. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: Guilford Press, 1998
69. Conners CK, Parker JD, Sitarenios G, et al. The revised Conners' parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnormal Child Psychol 1998 Aug; 26 (4): 257-268 (Pubitemid 28359774)
70. Shire plc. New analysis in boys and girls shows the ADHD patch, Daytrana™ offered ADHD symptom control for 12 months [ADHD news]. Medical News Today, 2008 May 8 [online]. Available from URL: http://www.medi- calnewstoday.com/articles/106671.php [Accessed 2009 Oct 4]
71. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31 (4): 345-354
72. Warshaw EM, Paller AS, Fowler JF, et al. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin Ther 2008 Feb; 30 (2): 326-337
73. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004 Apr; 113 (4): 762-769
74. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007 Aug; 46 (8): 1015-1027
75. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008 Jul; 13 (7): 614-620
76. Spencer TJ, Newcorn JH, Kratochvil CJ, et al. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/ hyperactivity disorder. Pediatrics 2005 Jul; 116 (1): E74-80
77. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007 Oct; 17 (5): 689-700
78. Faraone SV, Biederman J, Monuteaux M, et al. Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/ hyperactivity disorder on growth. J Child Adolesc Psychopharmacol 2005 Apr; 15 (2): 191-202 (Pubitemid 40734099)
79. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005 Oct; 44 (10): 1015-1023
80. Charach A, Figueroa M, Chen S, et al. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006 Apr; 45 (4): 415-421
81. Pliszka SR, Matthews TL, Braslow KJ, et al. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 May; 45 (5): 520-526
82. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009 Jun; 23 (4): 419-427
83. McGough JJ, Biederman J, Greenhill LL, et al. Pharmacokinetics of SLI381 (Adderall XR), an extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 2003 Jun; 42 (6): 684-691
84. Krishnan S, Zhang Y. Relative bioavailability of lisdex-amfetamoine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008 Mar; 48 (3): 293-302
85. Biederman J, Boellner SW, Childress A, et al. Lisdex-amfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007 Nov; 62 (9): 970-976
86. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and safety of lisdexamfeine (LDX; NRP104) in children with attention-deficit hyperactivity disorder: a phase 3, randomized, multicenter, double-blind, parallel-group study. Clin Ther 2007 Mar; 29 (3): 450-463
87. Wigal SB, Kollins SH, Childress AC, et al.; 311 Study Group. A 13-hour laboratory school study of lisdex-amfetamine dimesylate in school-aged youths with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009 Jun; 3 (1): 17
88. Easton N, Marshall F, Fone KC, et al. Differential effects of the d-and l-isomers of amphetamine on pharmacological MRI BOLD contrast in the rat. Psychopharmaco-logy (Berl) 2007 Jul; 193 (1): 11-30
89. Sagvolden T, Xu T. l-Amphetamne improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of attention-deficit/hyperactivity disorder (ADHD). Behav Brain Funct 2008 Jan; 4: 3
90. Glaser PE, Thomas TC, Joyce BM, et al. Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. Psycho-pharmacology (Berl) 2005 Mar; 178 (2-3): 250-258
91. Joyce BM, Glaser PE, Gerhardt GA. Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers. Psycho-pharmacology (Berl) 2007 Apr; 191 (3): 669-677
92. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psycho-pharmacol 2003 Spring; 13 (1): 53-63
93. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007 Feb; 46 (2): 242-251
94. Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharma-col 2008 Feb; 18 (2): 79-86
95. Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methyl-phenidate and desipramine. Drug Alcohol Depend 2004 Sep; 75 (3): 271-276
96. Jasinski DR, Faries DE, Moore RJ, et al. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008 May; 95 (1-2): 140-146
97. Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007 Mar; 61 (5): 694-699
98. Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of ato-moxetine in children and adults with attention deficit/ hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 2004 Feb; 24 (1): 30-35
99. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperacti-vity disorder. J Clin Psychiatry 2002 Dec; 63 (12): 1140-1147
100. Michelson D, Faries D, Wernicke J, et al., Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperacti-vity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 10 (5): E83
101. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159 (11): 1896-1901
102. Cheng JY, Chen RY, Ko JS, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007 Oct; 194 (2): 197-209
103. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005 Sep; 22 (5): 498-512
104. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005 Aug; 9 (1): 275-289
105. Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007 Mar; 41 (3): 222-230
106. Newcorn JH, Kratochvil CJ, Allen AJ, et al., Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008 Jun; 165 (6): 721-730
107. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004 Jul; 43 (7): 896-904
108. Donnelly C, Bangs M, Trzepacz P, et al. Safety and toler-ability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009 Feb; 48 (2): 176-185
109. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 2006 Jul; 149 (1): 112-119
110. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Aug; 45 (8): 919-927
111. Public health advisory for atomoxetine: suicidal thinking in children and adolescents being treated with Strattera (atomoxetine) [online]. Available from URL: http://www. fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm 051733.htm [Accessed 2009 Jan 30]
112. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 209-1183
113. Atomoxetine ADHD and Comorbid MDD Study Group. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007 Aug; 17 (4): 407-420
114. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette's syndrome. J Atten Disord 2008 Jan; 11 (4): 470-481
115. Ledbetter M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol 2005 Apr; 15 (2): 331-333
116. Parraga HC, Parraga KL, Harris DK, et al. Abdominal tics during atomoxetine treatment in a child with ADHD: evaluation and differential diagnosis. CNS Spectr 2008 Sep; 13 (9): E1
117. Parraga HC, Parraga MI, Harris DK. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med 2007; 37 (4): 415-424
118. Sears J, Patel NC. Development of tics in a thirteen-year-old male following atomoxetine use. CNS Spectr 2008 Apr; 13 (4): 301-303
119. Geller D, DonnellyC, LopezF, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007 Sep; 46 (9): 1119-1127
120. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008 Feb; 121 (2): E314-20
121. Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention def-icit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005; 44 (3): 240-248
122. Biederman J, Spencer TJ, Newcorn JH, et al. Effect of co-morbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psycho-pharmacology (Berl) 2007 Jan; 190 (1): 31-41
123. Hazell P, Zhang S, Wolanczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/ hyperactivity disorder. Eur Child Adolesc Psychiatry 2006 Mar; 15 (2): 105-110
124. Ji XH, Ji JZ, Zhang H, et al. Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat. Neuropsycho-pharmacology 2008 Aug; 33 (9): 2263-2271
125. LevyF. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct 2008 Feb; 4: 12
126. Wang M, Ramos BP, Paspalas CD, et al. Alpha 2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007 Apr; 129 (2): 397-410
127. Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention deficit-hyperactivity disorder. Pharmacotherapy 2007 Sep; 27 (9): 1253-1262
128. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyper-activity disorder. J Am Acad Child Adolesc Psychiatry 1995 Jan; 34 (1): 50-54
129. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995 Sep; 34 (9): 1140-1146
130. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001 Jul; 158 (7): 1067-1074
131. Shire U.S. Inc. Intuniv™ (guanfacine) Extended Release Tablets: highlights of prescribing information [online]. Available from URL:http://www.intuniv.com/documents/ INTUNIV-Full-Prescribing-lnformation.pdf [Accessed 2009 Nov 15]
132. Biederman J, Melmed RD, Patel A, et al., SPD503 Study Group. A randomized, double blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008 Jan; 121(1): E73-84
133. Sallee F, McGough J, Wigal T, et al., SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009 Feb; 48 (2): 155-165
134. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfaciine extended release in children and adolescents with ADHD. CNS Spectr 2008 Dec; 13 (12): 1047-1055
135. Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19 (3): 215-226
136. Choi Y, Novak JC, Hillier A, et al. The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility. Cogn Behav Neurol 2006 Dec; 19 (4): 204-207
137. The Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002 Feb; 58: 527-536
138. Palumbo DR, Sallee FR, Pelham WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 180-188
139. Daviss WB, Patel NC, Robb AS. Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47 (2): 189-198
140. Nair V, Mahadevan S. Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD. J Trop Pediatr 2009 Apr; 55 (2): 116-121
141. Addrenex Pharmaceuticals. Addrenex Pharmaceuticals files sNDA submission for Clonicel to treat ADHD [press release]. 2009 Oct 1 [online]. Available from URL: http:// www.addrenex.com/Addrenex-Clonicel-10-01-2009.pdf [Accessed 2009 Oct 4]
142. Addrenex Pharmaceuticals announces positive phase III clinical results for Clonicel to treat ADHD [online]. Available from URL: http://www.addrenex. com/Addrenex-Press09-10-2008.pdf [Accessed 2009 Jan 15]
143. Addrenex Pharmaceuticals reports positive results in second phase 3 study of ADHD medication [online]. Available from URL: http://www.addrenex.com/ PressR-ADHD-04-23-2009.pdf [Accessed 2009 Jul 17]
144. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999 Dec; 38 (12): 1551-1559
145. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch Pediatr Adolesc Med 2002 May; 156 (5): 504-511
146. Schlander M. Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence. Child Adolesc Psychiatry Ment Health 2007 Nov; 1 (1): E13
147. Cottrell S, Tilden D, Robinson P, et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/ hyperactivity disorder in the United Kingdom. Value Health 2008 May-Jun; 11 (3): 376-388
148. Hong J, Dilla T, Arellano J. A modeled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry 2009 Apr; 9: E15
149. Rx product listing. In: Red book: pharmacy's fundamental reference. 2009 ed. Montvale (NJ): Thompson Reuters, 2009: 173-816
150. Steele M, Jensen PS, Quinn D, et al. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006 Nov; 28 (11): 1892-1908
151. Buitelaar JK, Wilens TE, Zhang S, et al. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry 2008 Oct; 50 (3): 335-342
152. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006 Jul; 10 (23): 1-146
153. Svanborg P, Thernlund G, Gustafsson PA, et al. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. Epub 2009 May 23
154. Varni JW, Burwinkle TM. The PedsQL as a patient-reported outcome in children and adolescents with atten-tion-deficit/hyperactivity disorder: a population-based study. Health Qual Life Outcomes 2006 Apr; 4: 26
155. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention deficit/hyperactivity disorder. Pediatrics 2004; 114 (5): E541-47
156. Yang P, Hsu HY, Chiou SS, et al. Health-related quality of life in methylphenidate-treated children with atten-tion-deficit-hyperactivity disorder: results from a Taiwanese sample. Aust N Z J Psychiatry 2007 Dec; 41 (12): 998-1004
157. Foster EM, Jensen PS, Schlander M, et al. Treatment for ADHD: Is more complex treatment cost-effective for more complex cases? Health Serv Res 2007 Feb; 42 (1 Pt 1): 165-182
158. Schlander M. Long-acting medications for the hyperkinetic disorders: a note on cost-effectiveness. Eur Child Adolesc Psychiatry 2007 Oct; 16 (7): 421-429
159. Weiss MD, Gadow K, Wasdell MB. Effectiveness outcomes in attention-deficit hyperactivity disorder. J Clin Psychiatry 2006; 67 Suppl. 8: 38-45
160. Shire Pharmaceuticals. Shire receives approvable letter from FDA for INTUNIV™ (guanfacine) extended release, a nonstimulant for the treatment of ADHD [online]. Available from URL: http://www.shire.com/shire/News AndMedia/PressReleases/showShirePress.jsp?tn=3&m1=8 &ref=799 [Accessed 2009 Jan 15]